LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

Home・Aandelen Lijst・Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals Inc

Gesloten

12.15 6.11

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

11.43

Max

12.42

Belangrijke statistieken
By Trading Economics
Inkomsten	-1.4M -14M
EPS	-0.15
Werknemers	37
EBITDA	-2.7M -15M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+174.78% upside

Dividenden
By Dow Jones
Volgende Winsten	6 aug 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-339M 1B
Vorige openingsprijs	6.04
Vorige sluitingsprijs	12.15

Technische score

By Trading Central

Vertrouwen

Strong Bearish Evidence

3.165 / 3.5827 Steun & Weerstand

Corvus Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

20 mei 2026, 23:31 UTC

Populaire aandelen

Stocks to Watch: Intuit, Applied Digital, Osisko, Banzai

20 mei 2026, 22:52 UTC

Belangrijke Marktbewegers

Osisko Shares Fall on Planned Convertible Notes Offering

20 mei 2026, 23:47 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

20 mei 2026, 23:47 UTC

Marktinformatie

Nikkei May Rise on Continued AI Enthusiasm -- Market Talk

20 mei 2026, 23:44 UTC

Winsten

Musk Is In Total Control of SpaceX. The IPO Filing Has Finally Come. -- Barrons.com

20 mei 2026, 23:35 UTC

Marktinformatie

Gold Edges Lower Amid Slightly Higher U.S. Treasury Yields -- Market Talk

20 mei 2026, 23:30 UTC

Marktinformatie

Goodman Well-Placed for Earnings Guidance Upgrade -- Market Talk

20 mei 2026, 23:17 UTC

Marktinformatie

Global Equities Roundup: Market Talk

20 mei 2026, 23:17 UTC

Marktinformatie

Ryman Healthcare Bull Focusing on Three Areas in FY26 Result -- Market Talk

20 mei 2026, 23:15 UTC

Marktinformatie

Mainfreight's FY26 Profit Fall May Mask Improving Performance -- Market Talk

20 mei 2026, 23:14 UTC

Winsten

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 4th Update

20 mei 2026, 23:02 UTC

Marktinformatie

KMD Brands Faces Two Testing Hurdles -- Market Talk

20 mei 2026, 22:57 UTC

Marktinformatie

Infratil's Other Assets Deserve Attention, Too -- Market Talk

20 mei 2026, 22:57 UTC

Marktinformatie

Global Energy Roundup: Market Talk

20 mei 2026, 22:57 UTC

Marktinformatie

Global Equities Roundup: Market Talk

20 mei 2026, 22:51 UTC

Marktinformatie

Australia Shares Set to Rise, Continue Whipsaw Week -- Market Talk

20 mei 2026, 22:51 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

20 mei 2026, 22:27 UTC

Marktinformatie

SpaceX Says It Has Largest Addressable Market in 'Human History' -- Market Talk

20 mei 2026, 22:14 UTC

Marktinformatie

Moody's Downgrades Mexico's Sovereign Rating -- Market Talk

20 mei 2026, 22:10 UTC

Winsten

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 3rd Update

20 mei 2026, 22:00 UTC

Winsten

Intuit Stock Falls on Earnings -- and the Company Plans to Cut 17% of Its Workforce -- Barrons.com

20 mei 2026, 21:38 UTC

Winsten

Acquisities, Fusies, Overnames

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 2nd Update

20 mei 2026, 21:27 UTC

Winsten

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- Update

20 mei 2026, 21:20 UTC

Winsten

Nvidia CFO: Edge Computing Demand Fell Modestly Due to Higher Memory Prices

20 mei 2026, 21:19 UTC

Winsten

Nvidia Still Uncertain Whether Shipping to China Will Be Allowed, CFO Says

20 mei 2026, 21:18 UTC

Winsten

Nvidia on Track to Start Production Shipments of Vera Rubin in Second Half of This Year, CFO Says

20 mei 2026, 21:17 UTC

Winsten

Nvidia Projects $20B in CPU Revenue This Year, CFO Says

20 mei 2026, 21:17 UTC

Winsten

Nvidia CFO: Every Major Hyperscaler Engaged in Deploying Vera CPU

20 mei 2026, 21:17 UTC

Winsten

Nvidia's Vera CPU Opens New $200B Market, CFO Says

20 mei 2026, 21:16 UTC

Winsten

SpaceX IPO Filing Finally Comes. Mars, Musk, and More Big Things to Watch. -- Barrons.com

Peer Vergelijking

Prijswijziging

Corvus Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

174.78% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 31.6 USD 174.78%

Hoogste 40 USD

Laagste 27 USD

Gebaseerd op 5 Wall Street-analisten die 12-maands prijsdoelen bieden voor Corvus Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

5 ratings

Buy

Hold

Sell

Gebaseerd op 5 analisten die aandelenratings hebben gegeven aan Corvus Pharmaceuticals Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

3.165 / 3.5827Steun & Weerstand

Recent bearish events outweigh bullish events.

All events are bearish.

Bearish events outweigh bullish events.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.